Find a Clinical Trial

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

18+

Learn more

TAP Block and minimally invasive hysterectomy for pain control

A randomized, controlled, observer-blinded pilot trial of laparoscopic large volume, multisite transversus abdominal plane (TAP) block with liposomal bupivacaine in patients undergoing minimally invasive hysterectomy for endometrial cancer

18-80

Learn more

Discovery

Discovery Approach to Ocular Hypertension

No minimum age

Learn more

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer

18-90

Learn more

Home and Bedside Visual Fields

Home and Bedside Visual Field Testing with Oleyes VisuALL Device

15-80

Learn more

Multi-spectral imaging

Label-free, multi-scale imaging for improved detection of ovarian cancer metastases

18-99

Learn more

Non- Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

Non-Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

18-100

Learn more

ETS3

Randomized Trial of Bifocal Spectacles vs. Single Vision Spectacles for Esotropia Greater at Near

3-9

Learn more

Infant Vision Health and Prenatal Drug Exposure

Single-Center Baseline Data on Vision Health in Infants with History of Prenatal Drug Exposure

0-5

Learn more

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

XPORT-EC-042 (GOG-3083): A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

18+

Learn more